September 16 - 19, 2015
Sheraton New York Times Square Hotel
New York, New York, USA
Abstract submission deadline: Wednesday, June 10
Advance registration deadline: Monday, July 27
1:30 p.m.-1:35 p.m.
Jill O’Donnell-Tormey, Cancer Research Institute, New York, New York
Keynote Address1:35 p.m.-2:05 p.m.
T cells as a drug for the personalized immunotherapy of cancerSteven A. Rosenberg, National Cancer Institute, Bethesda, Maryland
Plenary Session 1: Immune Regulation of T Cell Responses / Evolving Concepts in Cancer ImmunologySession Chairperson: James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, Texas2:05 p.m.-4:05 p.m.
Chairperson perspectiveImmune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for a cure James P. Allison
Biology of the PD-1 pathway Arlene H. Sharpe, Harvard Medical School, Boston, Massachusetts
Anti-tumor activity of immunomodulatory antibodies Alan Korman, Bristol-Myers Squibb, Redwood City, California
The interplay between L-arginine metabolism and adoptive immunity in cancer Vincenzo Bronte, Venetian Institute of Molecular Medicine, Padova, Italy
Tumor-derived CD103+ dendritic cells carry antigen to the tumor-draining lymph node and are essential for CD8+ T cell priming*Edward Roberts, University of California, San Francisco, California
Refreshment Break4:05 p.m.-4:35 p.m.
Plenary Session 2:
Tumor Antigens for Targeting: Insights from GenomicsSession Chairperson: Christoph Huber, Johannes Gutenberg University Mainz Medical Center, Mainz, Germany4:35 p.m.-6:35 p.m.
Chairperson perspective Christoph Huber
Personalizing cancer immunotherapy Robert D. Schreiber, Washington University School of Medicine, St. Louis, Missouri
Targeting the mutanome for individualized cancer immunotherapy Ugur Sahin, TRON Translational Cancer Center-Johannes Gutenberg University; BioNTech Biopharmaceutical New Technologies Corporation, Mainz, Germany
Impact of the immunogenic landscape of cancers on immunotherapyHans-Georg Rammensee, University of Tuebingen, Tuebingen, Germany
Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens*Todd D. Prickett, National Cancer Institute, Bethesda, Maryland
Poster Session A6:45 p.m.-8:45 p.m.
*Short talks from proffered abstracts
Top of page